Clinical Trials

220 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT04895709 2026-02-25

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

949 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02861573 2026-02-17

KEYNOTE-365

1,200 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT04633252 2026-01-16

M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer

86 enrolled

Prostatic Neoplasms

NCT06568094 2025-12-31

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

100 enrolled

Prostatic Neoplasms

NCT06615752 2025-11-12

Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients

99 enrolled

Prostatic Neoplasms

NCT06704191 2025-09-22

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

40 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

173 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

19 enrolled

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06480110 2025-04-13

Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer

30 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT03317158 2025-01-30

ADAPT-BLADDER

55 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06732531 2025-01-09

Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer

48 enrolled

Urinary Bladder Neoplasms

NCT03693612 2024-08-28

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

DermatologicGenitourinaryHead & NeckThoracic

26 enrolled 47 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms

NCT03837353 2023-12-18

A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

18 enrolled 15 charts

Prostatic Neoplasms

NCT02599324 2023-11-18

Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

263 enrolled 34 charts

Carcinoma, Renal Cell

NCT01234025 2023-10-06

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

113 enrolled

Castrate-Resistant Prostate Cancer

NCT03636256 2023-08-14

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

36 enrolled 18 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

NCT02494921 2022-08-31

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

43 enrolled 22 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT02565901 2021-10-01

Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

28 enrolled 8 charts

Prostatic Neoplasms

NCT01468532 2021-03-25

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

18 enrolled 15 charts

Prostatic Neoplasms

NCT02401542 2020-03-09

FIERCE-21

71 enrolled 9 charts

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Diseases

NCT01683994 2019-11-08

Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer

49 enrolled 18 charts

Prostatic Neoplasms

NCT00456989 2019-10-30

Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer

39 enrolled 4 charts

Prostatic Neoplasms

NCT01084655 2019-07-30

Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer

38 enrolled 29 charts

Prostatic Neoplasms

NCT00669162 2019-07-24

Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer

27 enrolled 7 charts

Prostatic Neoplasms

NCT03343977 2018-07-17

Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Phase 1/2 Withdrawn

Metastatic Hormone-Sensitive Prostate Cancer

NCT00225420 2017-06-01

NRR

23 enrolled 9 charts

Prostatic Neoplasms

NCT00879619 2017-02-01

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

4 enrolled 3 charts

Prostatic Neoplasms

NCT00861471 2016-06-30

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

24 enrolled 11 charts

Prostatic Neoplasms

NCT00503984 2016-06-09

A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients

22 enrolled 16 charts

Pain, Prostatic Neoplasms

NCT00459186 2016-05-16

The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer

19 enrolled 6 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT00514267 2015-08-13

An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors

32 enrolled

Neoplasms, Prostatic Neoplasms

NCT00539968 2015-02-05

A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)

BreastGastrointestinalGenitourinaryGynecologicThoracic

5 enrolled

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT00439270 2014-03-28

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

49 enrolled 25 charts

Prostatic Neoplasms

NCT00002775 2014-01-06

Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

Phase 1/2 Unknown

37 enrolled

Prostatic Neoplasms

NCT00003103 2013-07-03

Chemotherapy in Treating Patients With Solid Tumors

BreastCNSGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

57 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Wilms Tumor, Ovarian Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Esthesioneuroblastoma, Olfactory

NCT00074022 2013-01-24

GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors

48 enrolled

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms

NCT00293371 2012-10-11

Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer

6 enrolled

Prostatic Neoplasms

NCT00448734 2009-01-21

A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer

Phase 1/2 Unknown

95 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT00121095 2007-12-21

Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer

Phase 1/2 Unknown

69 enrolled

Prostatic Neoplasms

NCT00283829 2007-11-29

Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer

30 enrolled

Prostatic Neoplasms

NCT00115635 2007-10-02

Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer

60 enrolled